The high gene alteration rate of PTPN3 was detected in uterine corpus endometrial carcinoma, bladder urothelial carcinoma, skin cutaneous melanoma, stomach adenocarcinoma, cholangiocarcinoma, colorectal adenocarcinoma, and lung squamous cell carcinoma with > 2% mutation frequency (Fig. 3A). This evidence concerns the gene PTPN3 and bladder transitional cell carcinoma.